Rhinosinusitis: Latest News, Top Stories & Analysis

Optinose’s XHANCE Added to Express Scripts’ National Formularies

June 28, 2024June 27, 2024 - by Timothy Alexander

YARDLEY, PA — Optinose (NASDAQ: OPTN) announced this week that its drug XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies. These include the National Preferred, Flex, and …

Regional

Optinose Targets Broad Market with FDA-Approved Sinusitis Treatment XHANCE

April 27, 2024April 26, 2024 - by Timothy Alexander

YARDLEY, PA — Pharmaceutical company Optinose has outlined an ambitious commercial strategy following the FDA’s recent approval of XHANCE (fluticasone propionate) for a new indication in treating chronic rhinosinusitis without …